热门资讯> 正文
第11章的Clearside Biomedical文件
2025-11-24 20:28
- Clearside Biomedical (CLSD) filed for voluntary Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware as of November 24, 2025.
- The company is pursuing a strategic sale of its business through a structured Chapter 11 process aimed at maximizing stakeholder value.
- As part of the bankruptcy case, Clearside (CLSD) intends to conduct an auction and sale process allowing interested parties to submit binding offers to acquire Clearside's assets, free and clear of liens and interests.
- The stock price tumbled ~70% to $0.82 on Monday during pre-market hours of trading.
More on Clearside Biomedical
- Seeking Alpha’s Quant Rating on Clearside Biomedical
- Historical earnings data for Clearside Biomedical
- Financial information for Clearside Biomedical
推荐文章
千亿资金需求下 OpenAI本周在ChatGPT上线广告
华盛早报 | 美股、金银全线暴跌，纳指跌超2%！韩国人再度扫货中国股票，大举买入MINIMAX、澜起科技；节前央行1万亿元买断式逆回购来了
美国联邦贸易委员会：苹果新闻偏袒左翼媒体、打压保守派内容
美股机会日报 | 就业数据转弱！美国至2月7日当周初请失业金人数超预期；存储概念股盘前齐升，闪迪大涨超7%
要点速递！《跑赢美股》春节特别直播核心观点总结
道指“一枝独秀”连创新高！特朗普喊话还能翻倍，轮动行情下如何平稳“上车”价值股ETF？
华盛早报 | 非农数据大超预期！首次降息或延至7月；AI恐慌交易蔓延至房地产服务板块， CBRE暴跌12%；智谱发布新模型
美股机会日报 | 经济数据强劲！美国1月非农就业大超预期，纳指期货涨至0.6%；AI应用股业绩超预期，Shopify涨超10%
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
